Ian Frazer

Scottish-born Australian immunologist
verifiedCite
While every effort has been made to follow citation style rules, there may be some discrepancies. Please refer to the appropriate style manual or other sources if you have any questions.
Select Citation Style
Feedback
Corrections? Updates? Omissions? Let us know if you have suggestions to improve this article (requires login).
Thank you for your feedback

Our editors will review what you’ve submitted and determine whether to revise the article.

External Websites
Britannica Websites
Articles from Britannica Encyclopedias for elementary and high school students.
Quick Facts
Born:
January 6, 1953, Glasgow, Scotland (age 71)
Awards And Honors:
Australian of the Year (2006)

Ian Frazer (born January 6, 1953, Glasgow, Scotland) is a Scottish-born Australian immunologist, whose research led to the development of a vaccine against the strains of human papillomavirus (HPV) that cause most cervical cancers.

In 1977 Frazer obtained a medical degree from the University of Edinburgh, where he received training as a renal physician and clinical immunologist. He immigrated to Australia in 1981 and became a citizen in 1998. In the early 1980s he conducted medical research on the hepatitis B virus at the Walter and Eliza Hall Institute in Melbourne. He transferred to the Princess Alexandra Hospital near downtown Brisbane in 1985 to study HPV. A few years later Frazer founded and became the director of the University of Queensland’s Centre for Immunology and Cancer Research at the hospital.

Frazer was among the first scientists to study the link between HPV infections and cervical cancer, one of the most common cancers for women. The strains of HPV that cause cervical cancer are transmitted by sexual contact and infect cells of the cervix (the outer end of the uterus). Such infections are common and usually clear up with no symptoms. In some cases, however, the infection persists, and the cells of the cervix become abnormal. These abnormal cells can eventually become cancerous. In 1991 Frazer and his colleague Jian Zhou succeeded in making viruslike particles that trigger an immune response against HPV and form the basis of the vaccine. Merck & Co., Inc., which developed the vaccine under the name Gardasil, conducted clinical trials that by October 2005 had shown the vaccine to be highly effective in protecting women against infections by two strains of HPV that caused 70 percent of cervical cancers and two strains that caused 90 percent of genital warts. In developed countries cervical cancer rates had been greatly reduced through the routine use of the Pap test, which detects abnormal cells of the cervix before they become cancerous. Frazer saw the greatest benefit of the vaccine to be for women in less-developed countries, and he worked with several organizations that could sponsor programs that would make the vaccine available to them. In recognition for his work on the HPV vaccine, Frazer was named Australian of the Year in 2006.

This article was most recently revised and updated by Encyclopaedia Britannica.